Raymond James Initiates Coverage On Cogent Biosciences with Strong Buy Rating, Announces Price Target of $30

Benzinga · 09/03/2025 16:46
Raymond James analyst Chris Raymond initiates coverage on Cogent Biosciences (NASDAQ:COGT) with a Strong Buy rating and announces Price Target of $30.